查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1662654

2030 年癌症治疗市场新型药物传递系统预测：按药物类型、输送方式、药物释放类型、技术、应用、最终用户和地区进行全球分析

Novel Drug Delivery Systems in Cancer Therapy Market Forecasts to 2030 - Global Analysis By Drug Type, Delivery Method, Drug Release Type, Technology, Application, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，肿瘤学新型药物输送系统的全球市场规模预计在 2024 年将达到 183.8 亿美元，到 2030 年将达到 316.9 亿美元，预测期内的复合年增长率为 9.5%。

将抗癌药物精确、有效分配到特定部位的先进技术称为癌症治疗中的新型药物传输系统。这些系统包括聚合物、脂质体、奈米颗粒等，旨在减少副作用、提高药物化合物的生物生物有效性并全面提高治疗效果。这些技术透过将药物直接输送到癌细胞和肿瘤，最大限度地提高治疗效果，同时减少对附近健康组织的伤害，为癌症治疗带来了希望。

个人化医疗日益受到关注

对个人化治疗的日益重视是推动癌症治疗新型药物输送系统 (NDDS) 市场发展的主要因素。个人化医疗根据患者的基因组成、分子特征和肿瘤特征制定治疗方案，可以实现更精确、更有效的癌症治疗。 NDDS 对这项策略至关重要，因为它们有助于将药物分布到特定的癌细胞，从而减少对良好组织的伤害并改善治疗效果。这种精确度可以减少副作用并提高患者对治疗计划的依从性。尖端 NDDS 技术的创造仍然是现代癌症治疗计划的重要组成部分，随着个人化医疗需求的增加，它支持了市场的扩张。

开发成本高

NDDS 所需的先进技术（如树状聚合物、脂质体和奈米粒子）需要独特​​的材料、复杂的製造程序和大量的经验。还需要进行大量的临床前和临床测试以确保这些系统的安全性和有效性。特别是在资源有限的环境中，这些高昂的费用可能使中小型公司难以进入市场，也可能导致治疗成本增加，限制患者获得治疗的机会。简而言之，NDDS 的开发成本阻碍了其广泛采用和商业化。

增加研发投入

对更有效、更有针对性和个人化的癌症治疗的需求日益增长，推动了对新型药物输送系统 (NDDS) 的研究和开发 (R&D) 投资的增加。研发工作重点是开发先进的药物传递技术，如奈米粒子、脂质体和胶束，以提高药物疗效、最大限度地减少副作用并提高患者的依从性。製药和生技公司也大力投资创新药物输送系统，以解决传统治疗方法的局限性，如生物有效性差和全身毒性。不断增加的研发投入正在加速开发新型、更有效、更安全的癌症治疗药物传递方法。

特定输送系统的临床证据有限

某些新型药物输送系统（NDDS）的临床资料缺乏仍然是癌症治疗市场的一个主要障碍。许多 NDDS 方法，包括某些奈米粒子配方和基于基因的递送系统，在临床前研究中已显示出良好的前景，但尚未在人体临床试验中证明持续有效。监管部门核准的延迟可能会阻碍这些技术的广泛应用。为了使新的 NDDS 技术成功并纳入标准癌症治疗，需要进行更彻底和大规模的临床测试以确定这些技术的风险和益处。

COVID-19 的影响

COVID-19 疫情对癌症治疗中使用的创新药物输送系统 (NDDS) 市场产生了重大影响。临床测试程序和供应链的中断推迟了新治疗方法的开发和核准。此外，由于医疗资源被重新用于应对新冠肺炎，对癌症治疗的关注度有所降低。此外，癌症患者在疫情期间更加脆弱，这使得他们的治疗计划更加复杂。这凸显了需要更有效率、更有针对性的药物传递系统来在这种充满挑战的环境下改善患者的治疗效果。

预测期内化疗药物领域预计将实现最大幅度成长

由于化疗药物在癌症治疗中的广泛应用，预计在预测期内将占据最大的市场占有率。 NDDS 技术可透过提高药物溶解度、更精准地针对癌细胞和降低全身毒性来增强化疗效果。这些系统可以实现控制释放，最大限度地减少副作用并最大限度地提高治疗效果。对改善化疗结果同时尽量减少副作用的需求日益增加，这加速了 NDDS 和化疗药物的进一步发展和整合。

预计预测期内医院部门将以最高的复合年增长率成长。

预计预测期内医院部门将呈现最高的成长率。作为领先的癌症治疗中心，该医院采用先进的 NDDS 来提高癌症治疗的效果、减少副作用并改善患者的治疗效果。临床实践中对个人化和标靶治疗的需求日益增长，鼓励医院投资这些创新的药物传递系统，最终促进它们的采用并加速它们融入标准癌症治疗方案。

比最大的地区

在预测期内，预计亚太地区将占据最大的市场占有率，这得益于癌症发病率的上升、医疗保健基础设施的改善以及医疗保健支出的增加。世界各国政府都在投资先进的医疗技术，对个人化医疗的认识不断增强，进一步推动了对 NDDS 的需求。此外，亚太地区庞大的患者群体，加上生物技术和製药行业的快速发展，使其成为开发和采用创新癌症治疗方案的关键市场。

复合年增长率最高的地区

预计北美地区在预测期内将呈现最高的复合年增长率。这是因为其拥有强大的医疗基础设施、先进的研发能力以及高昂的医疗成本。该地区对个人化癌症治疗的日益重视，加上对精准医疗的日益重视，正在推动对 NDDS 技术的需求。此外，FDA 等机构的监管支援以及主要製药和生物技术公司的存在正在加速北美癌症治疗创新药物传输系统的开发和采用。

免费客製化服务

订阅此报告的客户可享有以下免费自订选项之一：

  • 公司简介
    • 对其他市场参与企业（最多 3 家公司）进行全面分析
    • 主要企业的 SWOT 分析（最多 3 家公司）
  • 地理细分
    • 根据客户兴趣对主要国家进行市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争性基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第 2 章 前言

  • 概述
  • 相关利益者
  • 研究范围
  • 调查方法
    • 资料探勘
    • 资料分析
    • 资料检验
    • 研究途径
  • 研究资讯来源
    • 主要研究资讯来源
    • 二手研究资料资讯来源
    • 先决条件

第三章 市场走势分析

  • 介绍
  • 驱动程式
  • 限制因素
  • 机会
  • 威胁
  • 技术分析
  • 应用分析
  • 最终用户分析
  • 新兴市场
  • COVID-19 的影响

第 4 章 波特五力分析

  • 供应商的议价能力
  • 买家的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

第 5 章。

  • 介绍
  • 化疗药物
  • 免疫疗法
  • 标靶治疗
  • 荷尔蒙疗法
  • 基因治疗
  • 其他药物类型

6. 全球癌症治疗市场新型药物传输系统依输送方式划分

  • 介绍
  • 基于奈米颗粒的药物输送
  • 基于微球的药物输送
  • 基于脂质体的药物输送
  • 聚合物药物输送
  • 透过注射和输注输送药物
  • 植入式药物传输系统
  • 其他的

第 7 章 癌症治疗中新型药物传输系统的全球市场（按药物释放类型）

  • 介绍
  • 持续释放
  • 控释
  • 目标发布

8. 全球癌症治疗市场新型药物传输系统（按技术）

  • 介绍
  • 奈米科技
  • 生物技术
  • 聚合物药物传输系统
  • 脂质体和奈米粒子
  • 基因治疗输送系统
  • 其他的

第 9 章 全球癌症治疗市场新型药物传输系统的应用

  • 介绍
  • 乳癌
  • 肺癌
  • 大肠直肠癌
  • 摄护腺癌
  • 白血病
  • 其他的

第 10 章 全球新型药物输送系统癌症治疗市场（依最终用户划分）

  • 介绍
  • 医院
  • 癌症研究所
  • 专科门诊
  • 居家医疗
  • 其他的

第 11 章全球癌症治疗新型药物传输系统市场（按地区）

  • 介绍
  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 欧洲其他地区
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十二章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第十三章 公司概况

  • Johnson & Johnson
  • Pfizer Inc.
  • Novartis AG
  • Merck & Co., Inc.
  • Roche Holding AG
  • Eli Lilly and Company
  • AbbVie Inc.
  • Bristol-Myers Squibb Company
  • Sanofi SA
  • AstraZeneca PLC
  • GlaxoSmithKline PLC
  • Amgen Inc.
  • Celgene Corporation
  • Bayer AG
  • Teva Pharmaceutical Industries Ltd.
  • Gilead Sciences, Inc.
  • Biocon Limited
  • Mylan NV
Product Code: SMRC28515

According to Stratistics MRC, the Global Novel Drug Delivery Systems in Cancer Therapy Market is accounted for $18.38 billion in 2024 and is expected to reach $31.69 billion by 2030 growing at a CAGR of 9.5% during the forecast period. Advanced technologies created to improve the accurate and efficient distribution of cancer drugs to specific areas are referred to as novel drug delivery systems in cancer therapy. These systems, which include polymers, liposomes, and nanoparticles, are designed to decrease adverse effects, boost the bioavailability of medicinal compounds, and enhance treatment efficacy overall. These technologies provide promising options in cancer therapy by delivering medications directly to cancer cells or tumors, maximizing therapeutic efficacy while reducing harm to nearby healthy tissues.

Market Dynamics:

Driver:

Increased focus on personalized medicine

Growing emphasis on individualized care is a major factor propelling the market for novel drug delivery systems (NDDS) in cancer treatment. More accurate and efficient cancer treatments are made possible by personalized medicine, which adjusts treatment plans according to a patient's genetic composition, molecular profile, and tumor features. By making it easier to distribute medications to particular cancer cells, NDDS are essential to this strategy because they reduce harm to good tissue and improve therapy results. This accuracy lowers adverse effects and increases patient compliance with treatment plans. The creation of cutting-edge NDDS technology remains a vital part of contemporary cancer treatment plans, supporting market expansion as the need for tailored medicines increases.

Restraint:

High development costs

The sophisticated technologies needed for NDDS, like dendrimers, liposomes, and nanoparticles, require unique materials, intricate manufacturing procedures, and a great deal of experience. To guarantee the security and effectiveness of these systems, a great deal of preclinical and clinical testing is also required. Particularly in environments with limited resources, these exorbitant expenses may make it more difficult for smaller businesses to enter the market and may also lead to higher treatment costs, which would limit patient access. This means that the cost of developing NDDS prevents them from being widely adopted and commercialized.

Opportunity:

Growing research and development investments

The growing need for more effective, targeted, and personalized cancer treatments is driving an increase in research and development (R&D) investments in Novel Drug Delivery Systems (NDDS). R&D efforts are focused on developing advanced drug delivery technologies, such as nanoparticles, liposomes, and micelles, which enhance drug efficacy, minimize side effects, and improve patient compliance. Pharmaceutical and biotechnology companies are also investing heavily in innovative drug delivery systems to address the limitations of conventional therapies, such as poor bioavailability and systemic toxicity. Increased R&D investments accelerate the development of novel, more efficient, and safe drug delivery options for cancer treatment.

Threat:

Limited clinical evidence for certain delivery systems

Insufficient clinical data for specific Novel Drug Delivery Systems (NDDS) continues to be a major obstacle in the market for cancer treatments. Many NDDS methods, including specific nanoparticle formulations and gene-based delivery systems, have shown promise in preclinical research but have not yet proven to be consistently effective in human clinical trials. The widespread deployment of these technologies may be hampered by the potential delay in regulatory approval. For emerging NDDS technologies to succeed and be incorporated into standard cancer treatment, more thorough, extensive clinical trials are required to confirm the hazards and advantages of these technologies.

Covid-19 Impact

The COVID-19 pandemic has had a significant impact on the market for innovative drug delivery systems (NDDS) used in cancer treatment. The development and approval of new therapies have been delayed by disruptions in clinical trial procedures and supply chains. Cancer therapies also received less attention as a result of healthcare resources being redirected to COVID-19 management. Additionally, because cancer patients were more vulnerable during the pandemic, their treatment plans were more complex. This highlights the need for more efficient and focused medication delivery systems to improve patient outcomes in this difficult setting.

The chemotherapy drugs segment is expected to be the largest during the forecast period

The chemotherapy drugs segment is expected to account for the largest market share during the forecast period, due to their widespread use in cancer treatment. NDDS technologies enhance the effectiveness of chemotherapy by improving drug solubility, targeting cancer cells more precisely, and reducing systemic toxicity. These systems allow for controlled release, minimizing side effects and maximizing therapeutic impact. The growing need to improve chemotherapy outcomes while minimizing adverse effects fuels further development and integration of NDDS with chemotherapy agents.

The hospitals segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the hospitals segment is predicted to witness the highest growth rate, as primary centers for cancer treatment, hospitals are adopting advanced NDDS to enhance the efficacy of cancer therapies, reduce side effects, and improve patient outcomes. The increasing demand for personalized and targeted therapies in clinical settings pushes hospitals to invest in these innovative drug delivery systems, ultimately promoting their adoption and accelerating their integration into standard cancer treatment protocols.

Region with largest share:

During the forecast period, Asia Pacific region is expected to hold the largest market share, driven by rising cancer incidence, improving healthcare infrastructure, and increasing healthcare expenditure. Governments are investing in advanced medical technologies, while growing awareness of personalized medicine further boosts demand for NDDS. Additionally, the region's large patient population, combined with rapid advancements in biotechnology and pharmaceutical industries, positions Asia-Pacific as a key market for the development and adoption of innovative cancer treatment solutions.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, owing to robust healthcare infrastructure, advanced research and development capabilities, and high healthcare spending. The region's focus on precision medicine, along with a growing emphasis on personalized cancer treatments, fuels demand for NDDS technologies. Additionally, regulatory support from agencies like the FDA, along with the presence of leading pharmaceutical and biotech companies accelerates the development and adoption of innovative drug delivery systems for cancer therapy in North America.

Key players in the market

Some of the key players profiled in the Novel Drug Delivery Systems in Cancer Therapy Market include Johnson & Johnson, Pfizer Inc., Novartis AG, Merck & Co., Inc., Roche Holding AG, Eli Lilly and Company, AbbVie Inc., Bristol-Myers Squibb Company, Sanofi S.A., AstraZeneca PLC, GlaxoSmithKline PLC, Amgen Inc., Celgene Corporation, Bayer AG, Teva Pharmaceutical Industries Ltd., Gilead Sciences, Inc., Biocon Limited, and Mylan N.V.

Key Developments:

In June 2024, Bristol-Myers Squibb Company received FDA accelerated approval for KRAZATI (adagrasib) in combination with cetuximab, a targeted treatment for KRASG12C-mutated CRC patients who had undergone prior chemotherapy, based on ORR and DOR results.

In January 2024, Johnson & Johnson acquired Ambrx Biopharma, a clinical-stage biopharmaceutical company, in a cash merger deal valued at approximately USD 2.0 billion, with estimated cash on hand deducted.

Drug Types Covered:

  • Chemotherapy Drugs
  • Immunotherapy Drugs
  • Targeted Therapy Drugs
  • Hormonal Therapy Drugs
  • Gene Therapy Drugs
  • Other Drug Types

Delivery Methods Covered:

  • Nanoparticle-Based Drug Delivery
  • Microsphere-Based Drug Delivery
  • Liposome-Based Drug Delivery
  • Polymeric Drug Delivery
  • Injection & Infusion Drug Delivery
  • Implantable Drug Delivery Systems
  • Other Delivery Methods

Drug Release Types Covered:

  • Sustained Release
  • Controlled Release
  • Targeted Release

Technologies Covered:

  • Nanotechnology
  • Biotechnology
  • Polymeric Drug Delivery Systems
  • Liposomes and Nanoparticles
  • Gene Therapy Delivery Systems
  • Other Technologies

Applications Covered:

  • Breast Cancer
  • Lung Cancer
  • Colorectal Cancer
  • Prostate Cancer
  • Leukemia
  • Other Applications

End Users Covered:

  • Hospitals
  • Cancer Research Institutes
  • Specialty Clinics
  • Home Care Settings
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Technology Analysis
  • 3.7 Application Analysis
  • 3.8 End User Analysis
  • 3.9 Emerging Markets
  • 3.10 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Type

  • 5.1 Introduction
  • 5.2 Chemotherapy Drugs
  • 5.3 Immunotherapy Drugs
  • 5.4 Targeted Therapy Drugs
  • 5.5 Hormonal Therapy Drugs
  • 5.6 Gene Therapy Drugs
  • 5.7 Other Drug Types

6 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Delivery Method

  • 6.1 Introduction
  • 6.2 Nanoparticle-Based Drug Delivery
  • 6.3 Microsphere-Based Drug Delivery
  • 6.4 Liposome-Based Drug Delivery
  • 6.5 Polymeric Drug Delivery
  • 6.6 Injection & Infusion Drug Delivery
  • 6.7 Implantable Drug Delivery Systems
  • 6.8 Other Delivery Methods

7 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Drug Release Type

  • 7.1 Introduction
  • 7.2 Sustained Release
  • 7.3 Controlled Release
  • 7.4 Targeted Release

8 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Technology

  • 8.1 Introduction
  • 8.2 Nanotechnology
  • 8.3 Biotechnology
  • 8.4 Polymeric Drug Delivery Systems
  • 8.5 Liposomes and Nanoparticles
  • 8.6 Gene Therapy Delivery Systems
  • 8.7 Other Technologies

9 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Application

  • 9.1 Introduction
  • 9.2 Breast Cancer
  • 9.3 Lung Cancer
  • 9.4 Colorectal Cancer
  • 9.5 Prostate Cancer
  • 9.6 Leukemia
  • 9.7 Other Applications

10 Global Novel Drug Delivery Systems in Cancer Therapy Market, By End User

  • 10.1 Introduction
  • 10.2 Hospitals
  • 10.3 Cancer Research Institutes
  • 10.4 Specialty Clinics
  • 10.5 Home Care Settings
  • 10.6 Other End Users

11 Global Novel Drug Delivery Systems in Cancer Therapy Market, By Geography

  • 11.1 Introduction
  • 11.2 North America
    • 11.2.1 US
    • 11.2.2 Canada
    • 11.2.3 Mexico
  • 11.3 Europe
    • 11.3.1 Germany
    • 11.3.2 UK
    • 11.3.3 Italy
    • 11.3.4 France
    • 11.3.5 Spain
    • 11.3.6 Rest of Europe
  • 11.4 Asia Pacific
    • 11.4.1 Japan
    • 11.4.2 China
    • 11.4.3 India
    • 11.4.4 Australia
    • 11.4.5 New Zealand
    • 11.4.6 South Korea
    • 11.4.7 Rest of Asia Pacific
  • 11.5 South America
    • 11.5.1 Argentina
    • 11.5.2 Brazil
    • 11.5.3 Chile
    • 11.5.4 Rest of South America
  • 11.6 Middle East & Africa
    • 11.6.1 Saudi Arabia
    • 11.6.2 UAE
    • 11.6.3 Qatar
    • 11.6.4 South Africa
    • 11.6.5 Rest of Middle East & Africa

12 Key Developments

  • 12.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 12.2 Acquisitions & Mergers
  • 12.3 New Product Launch
  • 12.4 Expansions
  • 12.5 Other Key Strategies

13 Company Profiling

  • 13.1 Johnson & Johnson
  • 13.2 Pfizer Inc.
  • 13.3 Novartis AG
  • 13.4 Merck & Co., Inc.
  • 13.5 Roche Holding AG
  • 13.6 Eli Lilly and Company
  • 13.7 AbbVie Inc.
  • 13.8 Bristol-Myers Squibb Company
  • 13.9 Sanofi S.A.
  • 13.10 AstraZeneca PLC
  • 13.11 GlaxoSmithKline PLC
  • 13.12 Amgen Inc.
  • 13.13 Celgene Corporation
  • 13.14 Bayer AG
  • 13.15 Teva Pharmaceutical Industries Ltd.
  • 13.16 Gilead Sciences, Inc.
  • 13.17 Biocon Limited
  • 13.18 Mylan N.V.

List of Tables

  • Table 1 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Type (2022-2030) ($MN)
  • Table 3 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Chemotherapy Drugs (2022-2030) ($MN)
  • Table 4 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Immunotherapy Drugs (2022-2030) ($MN)
  • Table 5 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Therapy Drugs (2022-2030) ($MN)
  • Table 6 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hormonal Therapy Drugs (2022-2030) ($MN)
  • Table 7 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Drugs (2022-2030) ($MN)
  • Table 8 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Drug Types (2022-2030) ($MN)
  • Table 9 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Delivery Method (2022-2030) ($MN)
  • Table 10 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanoparticle-Based Drug Delivery (2022-2030) ($MN)
  • Table 11 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Microsphere-Based Drug Delivery (2022-2030) ($MN)
  • Table 12 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposome-Based Drug Delivery (2022-2030) ($MN)
  • Table 13 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery (2022-2030) ($MN)
  • Table 14 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Injection & Infusion Drug Delivery (2022-2030) ($MN)
  • Table 15 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Implantable Drug Delivery Systems (2022-2030) ($MN)
  • Table 16 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Delivery Methods (2022-2030) ($MN)
  • Table 17 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Drug Release Type (2022-2030) ($MN)
  • Table 18 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Sustained Release (2022-2030) ($MN)
  • Table 19 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Controlled Release (2022-2030) ($MN)
  • Table 20 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Targeted Release (2022-2030) ($MN)
  • Table 21 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Technology (2022-2030) ($MN)
  • Table 22 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Nanotechnology (2022-2030) ($MN)
  • Table 23 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Biotechnology (2022-2030) ($MN)
  • Table 24 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Polymeric Drug Delivery Systems (2022-2030) ($MN)
  • Table 25 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Liposomes and Nanoparticles (2022-2030) ($MN)
  • Table 26 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Gene Therapy Delivery Systems (2022-2030) ($MN)
  • Table 27 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Technologies (2022-2030) ($MN)
  • Table 28 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Application (2022-2030) ($MN)
  • Table 29 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Breast Cancer (2022-2030) ($MN)
  • Table 30 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Lung Cancer (2022-2030) ($MN)
  • Table 31 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Colorectal Cancer (2022-2030) ($MN)
  • Table 32 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Prostate Cancer (2022-2030) ($MN)
  • Table 33 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Leukemia (2022-2030) ($MN)
  • Table 34 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other Applications (2022-2030) ($MN)
  • Table 35 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By End User (2022-2030) ($MN)
  • Table 36 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 37 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Cancer Research Institutes (2022-2030) ($MN)
  • Table 38 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 39 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Home Care Settings (2022-2030) ($MN)
  • Table 40 Global Novel Drug Delivery Systems in Cancer Therapy Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.